1. Generics Bulletin

Neuraxpharm Recruits Another Viatris Executive To Lead European Expansion

Maximilian Von Wülfing Appointed To Newly-Created Post Of Chief Operating Officer

 
• By Dave Wallace

For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.

Hand grab wooden man recruitment appointment
Neuraxpharm has picked up another Viatris executive • Source: Alamy

For the second time in two months, Neuraxpharm has recruited a leading executive from Viatris to help continue to build out the central nervous system specialist’s business in Europe, today appointing Maximilian von Wülfing to the newly-created position of chief operating officer with immediate effect.

Boasting “over 15 years of international leadership experience in the pharmaceutical industry,” von Wülfing joins Neuraxpharm from Viatris – formerly Mylan – where he served as general manager for numerous countries in Europe, most recently as general

More from Leadership

More from Generics Bulletin

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.